Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02367794
Recruitment Status : Completed
First Posted : February 20, 2015
Results First Posted : November 12, 2019
Last Update Posted : April 13, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.

Condition or disease Intervention/treatment Phase
Squamous Non-Small Cell Lung Cancer Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody Drug: Carboplatin Drug: Nab-Paclitaxel Drug: Paclitaxel Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1021 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Actual Study Start Date : June 11, 2015
Actual Primary Completion Date : October 3, 2018
Actual Study Completion Date : February 17, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A: Atezolizumab + Paclitaxel + Carboplatin
The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
Other Name: Tecentriq

Drug: Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Drug: Paclitaxel
Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.

Experimental: Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
Other Name: Tecentriq

Drug: Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Drug: Nab-Paclitaxel
Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.

Active Comparator: Arm C: Nab-Paclitaxel + Carboplatin
The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
Drug: Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Drug: Nab-Paclitaxel
Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.




Primary Outcome Measures :
  1. Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
    PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.

  2. Overall Survival (OS) in the ITT Population [ Time Frame: Up to approximately 39 months after first participant enrolled ]
    OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.


Secondary Outcome Measures :
  1. OS in the Tumor Gene Expression (tGE) Population [ Time Frame: Up to approximately 39 months after first participant enrolled ]
  2. PFS as Determined by the Investigator Using RECIST v1.1 in the tGE Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  3. PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  4. PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  5. OS in the TC2/3 or IC2/3 Population [ Time Frame: Up to approximately 39 months after first participant enrolled ]
  6. OS in the TC1/2/3 or IC1/2/3 Population [ Time Frame: Up to approximately 39 months after first participant enrolled ]
  7. Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  8. Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  9. OS at 1 and 2 Years in the ITT Population [ Time Frame: 1 and 2 years ]
    OS rates at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population

  10. Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  11. TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population [ Time Frame: Up to approximately 30 months after the first participant enrolled ]
  12. Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population [ Time Frame: Baseline up to approximately 30 months after first participant enrolled ]
  13. PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A vs. Arm B) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
  14. OS in the ITT Population (Arm A vs. Arm B) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
  15. Percentage of Participants With Adverse Events [ Time Frame: Up to approximately 39 months after first participant enrolled ]
  16. Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab [ Time Frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days) ]
    The predose samples will be collected on the same day of treatment administration.

  17. Maximum Observed Serum Atezolizumab Concentration (Cmax) [ Time Frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle up to 39 months; 30 minutes postdose on Day 1 of Cycles 1 and 3; at treatment discontinuation (up to 39 months), and at 120 days after last dose of atezolizumab (up to 39 months, each cycle is 21 days) ]
    The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.

  18. Minimum Observed Serum Atezolizumab Concentration (Cmin) [ Time Frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days) ]
    The predose samples will be collected on the same day of treatment administration.

  19. Plasma Concentrations for Paclitaxel [ Time Frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) ]
  20. Plasma Concentrations for Nab-Paclitaxel [ Time Frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) ]
  21. Plasma Concentrations for Carboplatin [ Time Frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
  • Previously obtained archival tumor tissue or tissue obtained from biopsy at screening
  • Measurable disease as defined by RECIST v1.1
  • Adequate hematologic and end organ function

Exclusion Criteria:

  • Active or untreated central nervous system (CNS) metastasis
  • Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Pregnant or lactating women
  • History of autoimmune disease
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Positive test for Human Immunodeficiency Virus (HIV)
  • Active hepatitis B or hepatitis C
  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
  • Severe infection within 4 weeks prior to randomization
  • Significant history of cardiovascular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02367794


Locations
Hide Hide 242 study locations
Layout table for location information
United States, Arizona
Ironwood Cancer & Research Centers
Chandler, Arizona, United States, 85224
United States, Arkansas
Highlands Oncology Group
Rogers, Arkansas, United States, 72758
United States, California
Southern CA Permanente Med Grp
Bellflower, California, United States
Kaiser Permanente Oakland Medical Center
Oakland, California, United States, 94611
Kaiser Permanente - Sacramento Medical Center and Medical Offices
Sacramento, California, United States, 95825
Kaiser Permanente - San Leandro Medical Center
San Leandro, California, United States, 94577
Kaiser Permanente - Santa Clara
Santa Clara, California, United States, 95051
Kaiser Permanente; Oncology Clinical Trials
Vallejo, California, United States, 94589
Kaiser Permanente - Walnut Creek
Walnut Creek, California, United States, 94596
United States, Colorado
Rocky Mountain Cancer Center
Denver, Colorado, United States, 80218
United States, Connecticut
Danbury Hospital
Danbury, Connecticut, United States, 06810
United States, Florida
Holy Cross Hospital Inc
Fort Lauderdale, Florida, United States, 33308
SCRI Florida Cancer Specialists South
Fort Myers, Florida, United States, 33916
Florida Cancer Specialists
Palm Beach Gardens, Florida, United States, 33410
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States, 34952
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
Saint Petersburg, Florida, United States, 33705
United States, Georgia
University Cancer & Blood Center, LLC; Research
Athens, Georgia, United States, 30607
Northwest Georgia Oncology Centers P.C.
Carrollton, Georgia, United States, 30117
Central Georgia Cancer Care PC
Macon, Georgia, United States, 31201
Southeastern Regional Medical Center, Inc.
Newnan, Georgia, United States, 30265
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Joliet Oncology-Hematology; Associates, Ltd.
Joliet, Illinois, United States, 60435
Quincy Medical Group
Quincy, Illinois, United States, 62301
United States, Indiana
Fort Wayne Med Oncology & Hematology Inc
Fort Wayne, Indiana, United States, 46845
United States, Iowa
Hematology-Oncology; Associates of the Quad Cities
Bettendorf, Iowa, United States, 52722
Siouxland Hematology/Oncology
Sioux City, Iowa, United States, 51101
United States, Kentucky
Lahey Clinic Med Ctr
Lexington, Kentucky, United States, 02421
Norton Cancer Institute
Louisville, Kentucky, United States, 40202
United States, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
United States, Maine
New England Cancer Specialists
Scarborough, Maine, United States, 04074
United States, Massachusetts
Southcoast Health System; Southcoast Centers For Cancer Care
Fairhaven, Massachusetts, United States, 02719
United States, Michigan
St. Joseph Mercy Health System
Ann Arbor, Michigan, United States, 48106
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Minnesota
St. Luke's Regional Cancer Center
Duluth, Minnesota, United States, 55805
United States, Mississippi
Hematology and Oncology Associates at Bridgepoint
Tupelo, Mississippi, United States, 38801
United States, Montana
Billings Clinic
Billings, Montana, United States, 59102
United States, New Jersey
Valley Hospital; Oncology Research
Paramus, New Jersey, United States, 07652
Regional Cancer Care Associates LLC
Sewell, New Jersey, United States, 08080
United States, New York
Clinical Research Alliance
New Hyde Park, New York, United States, 11042-1083
United States, North Carolina
W.G. Bill Hefner VA Medical Center
Salisbury, North Carolina, United States
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45203-0542
Mark H. Zangmeister Center
Columbus, Ohio, United States, 43219
Oncology Hematology Care, Inc.
Hamilton, Ohio, United States, 45103
United States, Oregon
Oregon Health & Science Uni
Portland, Oregon, United States, 97239
United States, Pennsylvania
St. Luke's Cancer Care Associates
Bethlehem, Pennsylvania, United States, 18015
Maryland Oncology Hematology (Lanham) - USOR
Gettysburg, Pennsylvania, United States, 17325
Allegheny Cancer Center
Pittsburgh, Pennsylvania, United States, 15212
Univ of Pittsburgh Medical Ctr
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
SCRI Tennessee Oncology Chattanooga
Chattanooga, Tennessee, United States, 37404
Tennessee Cancer Specialists
Knoxville, Tennessee, United States, 37920
United States, Texas
SCRI The Center For Cancer and Blood Disorders
Denton, Texas, United States, 76210
Longview Cancer Center
Longview, Texas, United States, 75601
United States, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Blue Ridge Cancer Care
Roanoke, Virginia, United States, 24014
United States, Washington
Providence Regional Cancer Partnership
Everett, Washington, United States, 98201
Medical Oncology Associates
Spokane, Washington, United States, 99208
Argentina
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina, C1125ABD
Sanatorio Allende
Cordoba, Argentina, X5000JHQ
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina, F5300COE
Clínica Pergamino
Pergamino, Argentina, 2700
Fundacion Koriza
Santa Rosa, Argentina, 6300
Centro de Investigacion; Clinica - Clinica Viedma S.A.
Viedma, Argentina, R8500ACE
Australia, New South Wales
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia, 2050
Calvary Mater Newcastle; Medical Oncology
Waratah, New South Wales, Australia, 2298
Australia, Queensland
Prince Charles Hospital
Chermside, Queensland, Australia, 4032
Townsville Hospital
Townsville, Queensland, Australia, 4810
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Austin Health
Heidelberg, Victoria, Australia, 3084
Cabrini Hospital Malvern
Malvern, Victoria, Australia, 3144
Sunshine Hospital
St Albans, Victoria, Australia, 3021
Australia, Western Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
Austria
Paracelsus Medizinische Privatuniversität
Salzburg, Austria, 5020
Belgium
Cliniques Universitaires St-Luc
Bruxelles, Belgium, 1200
CHU Sart-Tilman
Liège, Belgium, 4000
Clinique Ste-Elisabeth
Namur, Belgium, 5000
Werken Glorieux VZW
Ronse, Belgium, 9600
GasthuisZusters Antwerpen
Wilrijk, Belgium, 2610
Brazil
Cenantron - Centro Avancado de Tratamento Oncologico
Belo Horizonte, MG, Brazil, 30130-090
Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica
Londrina, PR, Brazil, 86 015 520
Liga Norte Riograndense Contra O Câncer
Natal, RN, Brazil, 59040150
IPCEM; Instituto de Pesquisa de Estudos Multicêntricos
Caxias do Sul, RS, Brazil, 95070-560
Hospital Bruno Born
Lajeado, RS, Brazil, 95900-000
Hospital das Clinicas - UFRGS
Porto Alegre, RS, Brazil, 90035-903
Hospital Mae de Deus
Porto Alegre, RS, Brazil, 90470-340
*X*Fundação Pio XII Hospital de Câncer de Barretos
Barretos, SP, Brazil, 14784-400
Hospital de Base de Sao Jose do Rio Preto
Sao Jose do Rio Preto, SP, Brazil, 15090-000
Hospital Do Cancer A C Camargo
Sao Paulo, SP, Brazil, 01525-001
Bulgaria
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
Plovdiv, Bulgaria, 4000
Multiprofile Hospital for Active Treatment Serdika EOOD
Sofia, Bulgaria, 1303
Canada, Ontario
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada, L4M 6M2
William Osler Health Centre
Etobicoke, Ontario, Canada, M9V 1R8
Lakeridge Health Center
Oshawa, Ontario, Canada, L1J 2J2
Canada, Quebec
Cite de La Sante de Laval; Hemato-Oncologie
Laval, Quebec, Canada, H7M 3L9
Hôpital du Sacré-Coeur de Montreal
Montreal, Quebec, Canada, H4J 1C5
St. Jerome Medical Research
St. Jerome, Quebec, Canada, J7Z 5T3
Chile
Health & Care SPA
Santiago, Chile, 7500006
Sociedad de Investigaciones Medicas Ltda (SIM)
Temuco, Chile, 4810469
France
CHU de Grenoble
Grenoble, France, 38043
Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd
Le Mans, France, 72000
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, France, 69008
Clinique Clémentville
Montpellier, France, 34070
Hopital de La Source
Orleans, France, 45067
Centre Hospitalier Lyon Sud
Pierre Benite, France, 69495
Hopital de Pontchaillou; Service de Pneumologie
Rennes, France, 35033
Centre Hospitalier Regional Sud Reunion; Service de Pneumologie
Saint Pierre, France, 97448
CH de Saint Quentin
Saint Quentin, France, 2100
Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques
Toulon Cedex 9, France, 83800
Germany
Charite - Universitätsmedizin Berlin
Berlin, Germany, 12203
Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie
Bielefeld, Germany, 33611
Augusta Kranken-Anstalt gGmbH
Bochum, Germany, 44791
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
Dresden, Germany, 01307
St. Elisabethen Krankenhaus
Frankfurt am Main, Germany, 60487
Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie
Gerlingen, Germany, 70839
LungenClinic Großhansdorf GmbH
Großhansdorf, Germany, 22927
Krankenhaus Martha-Maria; Halle-Dolau gGmbH
Halle, Germany, 06120
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
Asklepios Klinik Harburg
Hamburg, Germany, 21075
Lungenklinik Hemer
Hemer, Germany, 58675
Universität Des Saarlandes; Klinik für Innere Medizin V
Homburg, Germany, 66421
Fachklinik für Lungenerkrankungen
Immenhausen, Germany, 34376
Kliniken der Stadt Koln gGmbH
Koln, Germany, 51109
Johannes Wesling Klinikum Minden
Minden, Germany, 32429
Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie
München, Germany, 81925
Krankenhaus Barmherzige Bruder Regensburg
Regensburg, Germany, 93049
Klinikum der Universität Regensburg
Regensburg, Germany, 93053
Stiftung Mathias-Spital Rheine
Rheine, Germany, 48431
Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
Villingen-Schwenningen, Germany, 78052
Israel
Soroka Medical Center
Beer Sheva, Israel, 8410101
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel, 9112001
Meir Medical Center; Oncology
Kfar-Saba, Israel, 4428164
Rabin Medical Center
Petach Tiqwa, Israel, 49100
Chaim Sheba Medical Center; Oncology Dept
Ramat Gan, Israel, 5262100
Rambam Health Corporation; Oncology Institute
Rambam, Israel, 3525408
Tel Aviv Sourasky Medical Ctr; Oncology
Tel Aviv, Israel, 6423906
Italy
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
Avellino, Campania, Italy, 83100
AORN A Cardarelli
Napoli, Campania, Italy, 80131
Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata
Napoli, Campania, Italy, 80131
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Napoli, Campania, Italy, 80131
Azienda Ospedaliera San Camillo Forlanini
Roma, Lazio, Italy, 00152
ASL 3 Genovese; DSM
Genova, Liguria, Italy, 16147
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardia, Italy, 27100
IRCCS Giovanni Paolo II Istituto Oncologico
Bari, Puglia, Italy, 70124
Policlinico Vittorio Emanuele
Catania, Sicilia, Italy, 95123
Ospedale Civile - Livorno
Livorno, Toscana, Italy, 57124
Azienda Ospedaliero Universitaria Pisana
Pisa, Toscana, Italy, 56100
Ospedale Silvestrini
Perugia, Umbria, Italy, 06122
Japan
Aichi Cancer Center Hospital; Respiratory Medicine
Aichi, Japan, 464-8681
Nagoya University Hospital; Respiratory Medicine
Aichi, Japan, 466-8560
National Cancer Center Hospital East; Thoracic Oncology
Chiba, Japan, 277-8577
National Hospital Organization Shikoku Cancer Center; Internal Medicine
Ehime, Japan, 791-0280
National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine
Fukuoka, Japan, 810-8563
Kyushu University Hospital; Respiratory
Fukuoka, Japan, 812-8582
Kobe City Medical Center General Hospital; Respiratory Medicine
Hyogo, Japan, 650-0047
National Hospital Organization Himeji Medical Center
Hyogo, Japan, 670-8520
Hyogo Cancer Center; Thoracic Oncology
Hyogo, Japan, 673-8558
Ibaraki Prefectural Central Hospital; Division of respiratory
Ibaraki, Japan, 309-1793
Kanagawa Cancer Center;Thoracic Oncology
Kanagawa, Japan, 241-8515
Kyoto University Hospital, Respiratory Medicine
Kyoto, Japan, 606-8507
Sendai Kousei Hospital; Pulmonary Medicine
Miyagi, Japan, 980-0873
Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease
Niigata, Japan, 951-8520
Okayama University Hospital; Respiratory and Allergy Medicine
Okayama, Japan, 700-8558
Osaka International Cancer Institute; Thoracic Oncology
Osaka, Japan, 541-8567
Osaka City Uni Hospital; Respiratory Medicine
Osaka, Japan, 545-8586
Kansai Medical university Hospital; Thoracic Oncology
Osaka, Japan, 573-1191
Osaka Habikino Medical Center
Osaka, Japan, 583-8588
Saitama Cancer Center; Thoracic Oncology
Saitama, Japan, 362-0806
National Hospital Organization Kinki-Chuo Chest Medical Center
Sakai-shi, Japan, 591-8555
Shizuoka Cancer Center; Thoracic Oncology
Shizuoka, Japan, 411-8777
National Cancer Center Hospital; Thoracic Medical Oncology
Tokyo, Japan, 104-0045
Tokyo Medical University Hospital; Dept of Surgery
Tokyo, Japan, 160-0023
Latvia
Riga East Clinical University Hospital Latvian Oncology Centre
Riga, Latvia, LV-1079
Pauls Stradins Clinical University Hospital
Rīga, Latvia, LV-1002
Lithuania
National Cancer Institute
Vilnius, Lithuania, 08660
Mexico
Centro Universitario Contra El Cancer
Monterrey, Mexico, 64020
Cancerología
Queretaro, Mexico, 76090
Netherlands
VU Medisch Centrum; VU University Medical Center
Amsterdam, Netherlands, 1007 MB
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands, 1066 CX
Ziekenhuis Gelderse Vallei
EDE, Netherlands, 6716 RP
Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose
Eindhoven, Netherlands, 5623 EJ
St. Antonius Ziekenhuis; R&D Long
Nieuwegein, Netherlands, 3435 CM
Peru
Centro Medico Monte Carmelo
Arequipa, Peru, 04001
Hospital Nacional Guillermo Almenara Irigoyen ESSALUD
Lima, Peru, Lima 13
Instituto Regional de Enfermedades Neoplásicas Del Norte
Trujillo, Peru, 12345
Portugal
IPO de Lisboa; Servico de Pneumologia
Lisboa, Portugal, 1099-023
Hospital Pulido Valente; Servico de Pneumologia
Lisboa, Portugal, 1796-001
Centro Hospitalar do Porto - Hospital de Santo António
Porto, Portugal, 4099-001
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
Porto, Portugal, 4200-072
Hospital de Sao Joao; Servico de Pneumologia
Porto, Portugal, 4200
Russian Federation
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation, 143423
Russian Oncology Research Center n.a. N.N. Blokhin
Moscow, Russian Federation, 115478
Clinical Oncology Dispensary
Omsk, Russian Federation, 644013
City Clinical Oncology Dispensary
Saint-Petersburg, Russian Federation, 197022
Volgograd Regional Clinical Oncology Dispensary
Volgograd, Russian Federation, 400138
Singapore
National University Hospital
Singapore, Singapore, 119074
National Cancer Centre
Singapore, Singapore, 169610
Slovakia
Univerzitna nemocnica Bratislava
Bratislava, Slovakia, 813 69
Narodny onkologicky ustav
Bratislava, Slovakia, 833 10
POKO Poprad s.r.o.
Poprad, Slovakia, 058 01
Spain
Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
Sabadell, Barcelona, Spain, 8208
Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
Santander, Cantabria, Spain, 39008
Hospital Universitario Son Espases
Palma De Mallorca, Islas Baleares, Spain, 07014
Complejo Hospitalario Universitario A Coruña
A Coruña, LA Coruña, Spain, 15006
Complejo Hospitalario Universitario Insular-Materno Infantil
Las Palmas de Gran Canaria, LAS Palmas, Spain, 35016
Hospital Nuestra Senora de Valme
Seville, Sevilla, Spain, 41014
Hospital Universitario de Canarias
S. Cristobal De La Laguna, Tenerife, Spain, 38320
Hospital del Mar
Barcelona, Spain, 08003
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain, 08035
Hospital Clinic de Barcelona
Barcelona, Spain, 08036
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
Barcelona, Spain, 08041
Hospital Universitario Reina Sofia
Cordoba, Spain, 14004
Hospital Lucus Augusti; Servicio de Oncologia
Lugo, Spain, 27003
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
Madrid, Spain, 28007
Hospital Universitario La Paz
Madrid, Spain, 280146
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, Spain, 28034
Fundación Jimenez Díaz
Madrid, Spain, 28040
Hospital Clinico San Carlos; Servicio de Oncologia
Madrid, Spain, 28040
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
Madrid, Spain, 28050
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Hospital General Universitario de Valencia
Valencia, Spain, 46014
Hospital Universitario Miguel Servet
Zaragoza, Spain, 50009
Taiwan
Changhua Christian Hospital; Hematology-Oncology
Changhua, Taiwan, 500
Kaohsiung Medical University Hospital; Department of Urology
Kaohsiung City, Taiwan, 807
Chi Mei Medical Center Liou Ying Campus
Liuying Township, Taiwan, 736
Chang Gung Memorial Hospital Chiayi
Putzu, Taiwan, 613
China Medical University Hospital
Taichung, Taiwan, 40447
National Taiwan Uni Hospital
Taipei City, Taiwan, 10041
Mackay Memorial Hospital
Taipei, Taiwan, 104
Ukraine
Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy
Dnipropetrovsk, Katerynoslav Governorate, Ukraine, 49102
Uzhgorod Central City Clinical Hospital
Uzhhorod, Katerynoslav Governorate, Ukraine, 88000
MNPE Zaporizhzhia Regional Antitumor Center ZRC
Zaporizhzhia, Katerynoslav Governorate, Ukraine, 69040
Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs
Kharkiv, Kharkiv Governorate, Ukraine, 61070
Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council
Vinnytsia, KIEV Governorate, Ukraine, 21029
MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy
Lviv, Volhynian Governorate, Ukraine, 79031
Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1
Chernivtsi, Ukraine, 58013
SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine
Kharkiv, Ukraine, 61024
ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department
Kryvyi Rih, Ukraine, 50048
Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department
Poltava, Ukraine, 36011
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
Sumy, Ukraine, 40005
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
  Study Documents (Full-Text)

Documents provided by Hoffmann-La Roche:
Study Protocol  [PDF] October 24, 2018
Statistical Analysis Plan  [PDF] January 11, 2018

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02367794    
Other Study ID Numbers: GO29437
2014-003208-59 ( EudraCT Number )
First Posted: February 20, 2015    Key Record Dates
Results First Posted: November 12, 2019
Last Update Posted: April 13, 2021
Last Verified: March 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Carboplatin
Atezolizumab
Antibodies
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs